Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Vladimir Skljarevski"'
Autor:
Michael Ament, Kathleen Day, Virginia L Stauffer, Vladimir Skljarevski, Mallikarjuna Rettiganti, Eric Pearlman, Sheena K. Aurora
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-10 (2021)
Abstract Background Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated a significant reduction in monthly migraine headache days compared with placebo. Here, we analyze data from 3 randomized cl
Externí odkaz:
https://doaj.org/article/7e0f3e29ff50462e83bb91f2aef26788
Autor:
Guochun Wang, Liqi Bi, Xiangpei Li, Zhijun Li, Dongbao Zhao, Jinwei Chen, Dongyi He, Chia-Ning Wang, Tao Wu, Héctor Dueñas, Vladimir Skljarevski, Li Yue
Publikováno v:
BMC Musculoskeletal Disorders, Vol 20, Iss 1, Pp 1-9 (2019)
Abstract Background The objectives of this study were to assess the maintenance of effect of duloxetine 60 mg once-daily (QD) in Chinese patients with chronic pain due to osteoarthritis (OA) of the knee or hip and to provide additional long-term safe
Externí odkaz:
https://doaj.org/article/34daa822c184418e8d1437dd730c1d9a
Autor:
Michael Ament, Kathleen Day, Virginia L. Stauffer, Vladimir Skljarevski, Mallikarjuna Rettiganti, Eric Pearlman, Sheena K. Aurora
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-2 (2021)
Externí odkaz:
https://doaj.org/article/5240f84726784d70ad35407c5199847a
Publikováno v:
Cephalalgia Reports, Vol 3 (2020)
Objective: This study was designed to assess the efficacy and safety of galcanezumab in comparison with placebo for the prevention of migraine in Japanese patients with episodic migraine. Methods: In this double-blind, placebo-controlled study, which
Externí odkaz:
https://doaj.org/article/89108d24659b4d1f9fe38767158a468e
Autor:
Russell Nichols, Vladimir Skljarevski, Grazia Dell’Agnello, Hans-Peter Hundemer, Sheena K. Aurora
Publikováno v:
The Journal of Headache and Pain, Vol 20, Iss 1, Pp 1-2 (2019)
Externí odkaz:
https://doaj.org/article/a03ed44d5a29483e9d556deb3df32ff7
Publikováno v:
Patient Preference and Adherence, Vol 2009, Iss default, Pp 31-43 (2009)
Eric Nantz1, Hong Liu-Seifert2, Vladimir Skljarevski21Department of Statistics, Western Michigan University, Kalamazoo, MI, USA; 2Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USABackground: Premature discontinuation of treatm
Externí odkaz:
https://doaj.org/article/adba965328fd478797c0f47e46aeff90
Autor:
Gretchen E. Tietjen, Vladimir Skljarevski, Todd A. Smitherman, Deborah N. D'Souza, Kory Schuh, Sarah Lipsius, Eric M. Pearlman
Publikováno v:
Headache
OBJECTIVE This post hoc analysis evaluated the efficacy of galcanezumab for the prevention of migraine in patients with and without comorbid anxiety and/or depression. BACKGROUND Patients with migraine have a higher risk of anxiety and/or depression.
Autor:
Dean Juge, Kushang V. Patel, Tina Tockarshewsky, Eric Devine, Lee S. Simon, John T. Farrar, Geertrui F. Vanhove, Michael P. McDermott, Michael C. Rowbotham, Richard Rauck, Dennis C. Turk, James N. Campbell, Ajay D. Wasan, Philip G. Conaghan, G. Niebler, Mark P. Jensen, Bernard Vrijens, Mittie K. Doyle, David J. Hewitt, Jennifer S. Gewandter, Neil Singla, Daniel B. Carr, Ernest A. Kopecky, Vladimir Skljarevski, Andrew S.C. Rice, Scott R. Evans, Robert D. Kerns, James Witter, Amy A. Kirkwood, Roy Freeman, Richard Malamut, Ian Gilron, Robert H. Dworkin, Nathaniel P. Katz, Penney Cowan, Robert R. Edwards, Nelson E. Sessler, Laurie B. Burke, John D. Markman
Publikováno v:
J Pain
The estimated probability of progressing from phase 3 analgesic clinical trials to regulatory approval is approximately 57%, suggesting that a considerable number of treatments with phase 2 trial results deemed sufficiently successful to progress to
Autor:
Yan Yolanda Cheng, Levent Alev, Jianing Wang, Shinji Fujikoshi, Vladimir Skljarevski, Li Yue, Hiroyuki Enomoto
Publikováno v:
Pain Practice
The objective of the present analysis was to determine whether changes in Brief Pain Inventory (BPI) average pain scores by patient global impression of improvement (PGI‐I) category and the cut‐off for clinically important difference (CID) were d
Autor:
Antje Tockhorn-Heidenreich, Richard B. Lipton, Janet H. Ford, David W. Ayer, Elizabeth Leroux, Sheena K. Aurora, Qi Zhang, Jeffrey N. Carter, Vladimir Skljarevski
Publikováno v:
Neurology. 93:e508-e517
ObjectiveTo evaluate changes from baseline in patient-reported outcomes for measures of functioning and disability among patients with migraine treated with galcanezumab or placebo.MethodsPatients with episodic migraine (4–14 monthly migraine heada